nodes	percent_of_prediction	percent_of_DWPC	metapath
Goserelin—LHCGR—Peptide GPCRs—CCR4—liver cancer	0.00254	0.0815	CbGpPWpGaD
Goserelin—Dyspnoea—Sorafenib—liver cancer	0.00238	0.00246	CcSEcCtD
Goserelin—LHCGR—Arf6 signaling events—HGF—liver cancer	0.00238	0.0764	CbGpPWpGaD
Goserelin—Dry eye—Doxorubicin—liver cancer	0.00237	0.00244	CcSEcCtD
Goserelin—Cramps of lower extremities—Doxorubicin—liver cancer	0.00235	0.00243	CcSEcCtD
Goserelin—Dyspepsia—Sorafenib—liver cancer	0.00235	0.00243	CcSEcCtD
Goserelin—Decreased appetite—Sorafenib—liver cancer	0.00232	0.0024	CcSEcCtD
Goserelin—Thrombophlebitis—Epirubicin—liver cancer	0.00232	0.0024	CcSEcCtD
Goserelin—Bladder pain—Doxorubicin—liver cancer	0.00232	0.00239	CcSEcCtD
Goserelin—Ecchymosis—Doxorubicin—liver cancer	0.00232	0.00239	CcSEcCtD
Goserelin—Neoplasm—Doxorubicin—liver cancer	0.00232	0.00239	CcSEcCtD
Goserelin—Diabetes mellitus—Epirubicin—liver cancer	0.00231	0.00239	CcSEcCtD
Goserelin—Fatigue—Sorafenib—liver cancer	0.0023	0.00238	CcSEcCtD
Goserelin—Hepatic function abnormal—Epirubicin—liver cancer	0.0023	0.00237	CcSEcCtD
Goserelin—Pain—Sorafenib—liver cancer	0.00229	0.00236	CcSEcCtD
Goserelin—Constipation—Sorafenib—liver cancer	0.00229	0.00236	CcSEcCtD
Goserelin—Hypertonia—Doxorubicin—liver cancer	0.00225	0.00232	CcSEcCtD
Goserelin—Sepsis—Doxorubicin—liver cancer	0.00222	0.00229	CcSEcCtD
Goserelin—Mental disability—Doxorubicin—liver cancer	0.00222	0.00229	CcSEcCtD
Goserelin—Cardiac failure congestive—Epirubicin—liver cancer	0.00222	0.00229	CcSEcCtD
Goserelin—Gastrointestinal pain—Sorafenib—liver cancer	0.00219	0.00226	CcSEcCtD
Goserelin—Hot flush—Epirubicin—liver cancer	0.00215	0.00222	CcSEcCtD
Goserelin—Thrombophlebitis—Doxorubicin—liver cancer	0.00215	0.00222	CcSEcCtD
Goserelin—Increased appetite—Epirubicin—liver cancer	0.00214	0.00221	CcSEcCtD
Goserelin—Diabetes mellitus—Doxorubicin—liver cancer	0.00214	0.00221	CcSEcCtD
Goserelin—Menopausal symptoms—Epirubicin—liver cancer	0.00213	0.0022	CcSEcCtD
Goserelin—Hepatic function abnormal—Doxorubicin—liver cancer	0.00213	0.0022	CcSEcCtD
Goserelin—Urticaria—Sorafenib—liver cancer	0.00212	0.00219	CcSEcCtD
Goserelin—Body temperature increased—Sorafenib—liver cancer	0.00211	0.00218	CcSEcCtD
Goserelin—Abdominal pain—Sorafenib—liver cancer	0.00211	0.00218	CcSEcCtD
Goserelin—Renal impairment—Epirubicin—liver cancer	0.00211	0.00218	CcSEcCtD
Goserelin—Cardiac failure—Epirubicin—liver cancer	0.00206	0.00213	CcSEcCtD
Goserelin—Lethargy—Epirubicin—liver cancer	0.00205	0.00212	CcSEcCtD
Goserelin—Cerebrovascular accident—Epirubicin—liver cancer	0.00205	0.00212	CcSEcCtD
Goserelin—Cardiac failure congestive—Doxorubicin—liver cancer	0.00205	0.00212	CcSEcCtD
Goserelin—Osteoarthritis—Epirubicin—liver cancer	0.00201	0.00207	CcSEcCtD
Goserelin—Hot flush—Doxorubicin—liver cancer	0.00199	0.00205	CcSEcCtD
Goserelin—Increased appetite—Doxorubicin—liver cancer	0.00198	0.00204	CcSEcCtD
Goserelin—Affect lability—Epirubicin—liver cancer	0.00198	0.00204	CcSEcCtD
Goserelin—Migraine—Epirubicin—liver cancer	0.00198	0.00204	CcSEcCtD
Goserelin—Menopausal symptoms—Doxorubicin—liver cancer	0.00197	0.00203	CcSEcCtD
Goserelin—Hypersensitivity—Sorafenib—liver cancer	0.00197	0.00203	CcSEcCtD
Goserelin—Renal impairment—Doxorubicin—liver cancer	0.00195	0.00202	CcSEcCtD
Goserelin—Asthenia—Sorafenib—liver cancer	0.00192	0.00198	CcSEcCtD
Goserelin—Cardiac failure—Doxorubicin—liver cancer	0.00191	0.00197	CcSEcCtD
Goserelin—Mood swings—Epirubicin—liver cancer	0.0019	0.00197	CcSEcCtD
Goserelin—Cerebrovascular accident—Doxorubicin—liver cancer	0.0019	0.00196	CcSEcCtD
Goserelin—Lethargy—Doxorubicin—liver cancer	0.0019	0.00196	CcSEcCtD
Goserelin—Pruritus—Sorafenib—liver cancer	0.00189	0.00195	CcSEcCtD
Goserelin—LHCGR—Arf6 signaling events—MET—liver cancer	0.00188	0.0603	CbGpPWpGaD
Goserelin—Osteoarthritis—Doxorubicin—liver cancer	0.00186	0.00192	CcSEcCtD
Goserelin—Dry skin—Epirubicin—liver cancer	0.00184	0.0019	CcSEcCtD
Goserelin—Affect lability—Doxorubicin—liver cancer	0.00183	0.00189	CcSEcCtD
Goserelin—Migraine—Doxorubicin—liver cancer	0.00183	0.00189	CcSEcCtD
Goserelin—Diarrhoea—Sorafenib—liver cancer	0.00183	0.00189	CcSEcCtD
Goserelin—Breast disorder—Epirubicin—liver cancer	0.00182	0.00187	CcSEcCtD
Goserelin—Dizziness—Sorafenib—liver cancer	0.00177	0.00182	CcSEcCtD
Goserelin—Mood swings—Doxorubicin—liver cancer	0.00176	0.00182	CcSEcCtD
Goserelin—Influenza—Epirubicin—liver cancer	0.00174	0.00179	CcSEcCtD
Goserelin—Dry skin—Doxorubicin—liver cancer	0.0017	0.00176	CcSEcCtD
Goserelin—GNRHR—Peptide GPCRs—CCR4—liver cancer	0.0017	0.0546	CbGpPWpGaD
Goserelin—Vomiting—Sorafenib—liver cancer	0.0017	0.00175	CcSEcCtD
Goserelin—Angina pectoris—Epirubicin—liver cancer	0.00169	0.00175	CcSEcCtD
Goserelin—Rash—Sorafenib—liver cancer	0.00169	0.00174	CcSEcCtD
Goserelin—Dermatitis—Sorafenib—liver cancer	0.00168	0.00174	CcSEcCtD
Goserelin—Breast disorder—Doxorubicin—liver cancer	0.00168	0.00173	CcSEcCtD
Goserelin—Headache—Sorafenib—liver cancer	0.00167	0.00173	CcSEcCtD
Goserelin—Bronchitis—Epirubicin—liver cancer	0.00167	0.00172	CcSEcCtD
Goserelin—Dysuria—Epirubicin—liver cancer	0.00162	0.00168	CcSEcCtD
Goserelin—Upper respiratory tract infection—Epirubicin—liver cancer	0.00161	0.00167	CcSEcCtD
Goserelin—Influenza—Doxorubicin—liver cancer	0.00161	0.00166	CcSEcCtD
Goserelin—Pollakiuria—Epirubicin—liver cancer	0.0016	0.00166	CcSEcCtD
Goserelin—Nausea—Sorafenib—liver cancer	0.00159	0.00164	CcSEcCtD
Goserelin—Photosensitivity reaction—Epirubicin—liver cancer	0.00159	0.00164	CcSEcCtD
Goserelin—Weight increased—Epirubicin—liver cancer	0.00158	0.00163	CcSEcCtD
Goserelin—Hyperglycaemia—Epirubicin—liver cancer	0.00157	0.00162	CcSEcCtD
Goserelin—Angina pectoris—Doxorubicin—liver cancer	0.00157	0.00162	CcSEcCtD
Goserelin—Pneumonia—Epirubicin—liver cancer	0.00156	0.00161	CcSEcCtD
Goserelin—Drowsiness—Epirubicin—liver cancer	0.00155	0.0016	CcSEcCtD
Goserelin—Bronchitis—Doxorubicin—liver cancer	0.00155	0.0016	CcSEcCtD
Goserelin—Renal failure—Epirubicin—liver cancer	0.00152	0.00157	CcSEcCtD
Goserelin—Jaundice—Epirubicin—liver cancer	0.00151	0.00156	CcSEcCtD
Goserelin—Urinary tract infection—Epirubicin—liver cancer	0.00151	0.00155	CcSEcCtD
Goserelin—Dysuria—Doxorubicin—liver cancer	0.0015	0.00155	CcSEcCtD
Goserelin—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00149	0.00154	CcSEcCtD
Goserelin—Sweating—Epirubicin—liver cancer	0.00149	0.00153	CcSEcCtD
Goserelin—Pollakiuria—Doxorubicin—liver cancer	0.00148	0.00153	CcSEcCtD
Goserelin—Haematuria—Epirubicin—liver cancer	0.00148	0.00152	CcSEcCtD
Goserelin—Photosensitivity reaction—Doxorubicin—liver cancer	0.00147	0.00151	CcSEcCtD
Goserelin—Weight increased—Doxorubicin—liver cancer	0.00146	0.00151	CcSEcCtD
Goserelin—Epistaxis—Epirubicin—liver cancer	0.00146	0.00151	CcSEcCtD
Goserelin—Sinusitis—Epirubicin—liver cancer	0.00145	0.0015	CcSEcCtD
Goserelin—Hyperglycaemia—Doxorubicin—liver cancer	0.00145	0.0015	CcSEcCtD
Goserelin—Pneumonia—Doxorubicin—liver cancer	0.00144	0.00149	CcSEcCtD
Goserelin—Drowsiness—Doxorubicin—liver cancer	0.00143	0.00148	CcSEcCtD
Goserelin—Renal failure—Doxorubicin—liver cancer	0.00141	0.00145	CcSEcCtD
Goserelin—Haemoglobin—Epirubicin—liver cancer	0.0014	0.00144	CcSEcCtD
Goserelin—Jaundice—Doxorubicin—liver cancer	0.0014	0.00144	CcSEcCtD
Goserelin—Rhinitis—Epirubicin—liver cancer	0.00139	0.00144	CcSEcCtD
Goserelin—Urinary tract infection—Doxorubicin—liver cancer	0.00139	0.00144	CcSEcCtD
Goserelin—Haemorrhage—Epirubicin—liver cancer	0.00139	0.00144	CcSEcCtD
Goserelin—Hepatitis—Epirubicin—liver cancer	0.00139	0.00144	CcSEcCtD
Goserelin—Pharyngitis—Epirubicin—liver cancer	0.00138	0.00142	CcSEcCtD
Goserelin—Sweating—Doxorubicin—liver cancer	0.00137	0.00142	CcSEcCtD
Goserelin—Urinary tract disorder—Epirubicin—liver cancer	0.00137	0.00142	CcSEcCtD
Goserelin—Oedema peripheral—Epirubicin—liver cancer	0.00137	0.00141	CcSEcCtD
Goserelin—Haematuria—Doxorubicin—liver cancer	0.00137	0.00141	CcSEcCtD
Goserelin—LHCGR—Ovarian Infertility Genes—CDKN1B—liver cancer	0.00137	0.0438	CbGpPWpGaD
Goserelin—Urethral disorder—Epirubicin—liver cancer	0.00136	0.00141	CcSEcCtD
Goserelin—Epistaxis—Doxorubicin—liver cancer	0.00135	0.0014	CcSEcCtD
Goserelin—Sinusitis—Doxorubicin—liver cancer	0.00134	0.00139	CcSEcCtD
Goserelin—Eye disorder—Epirubicin—liver cancer	0.0013	0.00134	CcSEcCtD
Goserelin—Haemoglobin—Doxorubicin—liver cancer	0.00129	0.00133	CcSEcCtD
Goserelin—Cardiac disorder—Epirubicin—liver cancer	0.00129	0.00133	CcSEcCtD
Goserelin—Rhinitis—Doxorubicin—liver cancer	0.00129	0.00133	CcSEcCtD
Goserelin—Hepatitis—Doxorubicin—liver cancer	0.00129	0.00133	CcSEcCtD
Goserelin—Haemorrhage—Doxorubicin—liver cancer	0.00129	0.00133	CcSEcCtD
Goserelin—Pharyngitis—Doxorubicin—liver cancer	0.00128	0.00132	CcSEcCtD
Goserelin—Urinary tract disorder—Doxorubicin—liver cancer	0.00127	0.00131	CcSEcCtD
Goserelin—Oedema peripheral—Doxorubicin—liver cancer	0.00127	0.00131	CcSEcCtD
Goserelin—Angiopathy—Epirubicin—liver cancer	0.00126	0.0013	CcSEcCtD
Goserelin—Urethral disorder—Doxorubicin—liver cancer	0.00126	0.0013	CcSEcCtD
Goserelin—Immune system disorder—Epirubicin—liver cancer	0.00126	0.0013	CcSEcCtD
Goserelin—Chills—Epirubicin—liver cancer	0.00125	0.00129	CcSEcCtD
Goserelin—Arrhythmia—Epirubicin—liver cancer	0.00124	0.00128	CcSEcCtD
Goserelin—Alopecia—Epirubicin—liver cancer	0.00123	0.00127	CcSEcCtD
Goserelin—Mental disorder—Epirubicin—liver cancer	0.00122	0.00126	CcSEcCtD
Goserelin—Erythema—Epirubicin—liver cancer	0.00121	0.00125	CcSEcCtD
Goserelin—Malnutrition—Epirubicin—liver cancer	0.00121	0.00125	CcSEcCtD
Goserelin—Eye disorder—Doxorubicin—liver cancer	0.0012	0.00124	CcSEcCtD
Goserelin—Cardiac disorder—Doxorubicin—liver cancer	0.00119	0.00123	CcSEcCtD
Goserelin—Flatulence—Epirubicin—liver cancer	0.00119	0.00123	CcSEcCtD
Goserelin—Tension—Epirubicin—liver cancer	0.00119	0.00123	CcSEcCtD
Goserelin—Nervousness—Epirubicin—liver cancer	0.00118	0.00121	CcSEcCtD
Goserelin—Back pain—Epirubicin—liver cancer	0.00117	0.00121	CcSEcCtD
Goserelin—Angiopathy—Doxorubicin—liver cancer	0.00117	0.0012	CcSEcCtD
Goserelin—Muscle spasms—Epirubicin—liver cancer	0.00116	0.0012	CcSEcCtD
Goserelin—Immune system disorder—Doxorubicin—liver cancer	0.00116	0.0012	CcSEcCtD
Goserelin—Chills—Doxorubicin—liver cancer	0.00115	0.00119	CcSEcCtD
Goserelin—Arrhythmia—Doxorubicin—liver cancer	0.00115	0.00119	CcSEcCtD
Goserelin—Vision blurred—Epirubicin—liver cancer	0.00114	0.00118	CcSEcCtD
Goserelin—Alopecia—Doxorubicin—liver cancer	0.00114	0.00117	CcSEcCtD
Goserelin—Mental disorder—Doxorubicin—liver cancer	0.00113	0.00116	CcSEcCtD
Goserelin—Ill-defined disorder—Epirubicin—liver cancer	0.00112	0.00116	CcSEcCtD
Goserelin—Erythema—Doxorubicin—liver cancer	0.00112	0.00116	CcSEcCtD
Goserelin—Malnutrition—Doxorubicin—liver cancer	0.00112	0.00116	CcSEcCtD
Goserelin—Anaemia—Epirubicin—liver cancer	0.00112	0.00115	CcSEcCtD
Goserelin—Flatulence—Doxorubicin—liver cancer	0.0011	0.00114	CcSEcCtD
Goserelin—Tension—Doxorubicin—liver cancer	0.0011	0.00113	CcSEcCtD
Goserelin—Malaise—Epirubicin—liver cancer	0.00109	0.00113	CcSEcCtD
Goserelin—Nervousness—Doxorubicin—liver cancer	0.00109	0.00112	CcSEcCtD
Goserelin—Leukopenia—Epirubicin—liver cancer	0.00108	0.00112	CcSEcCtD
Goserelin—Back pain—Doxorubicin—liver cancer	0.00108	0.00112	CcSEcCtD
Goserelin—Muscle spasms—Doxorubicin—liver cancer	0.00108	0.00111	CcSEcCtD
Goserelin—Palpitations—Epirubicin—liver cancer	0.00107	0.0011	CcSEcCtD
Goserelin—Cough—Epirubicin—liver cancer	0.00106	0.00109	CcSEcCtD
Goserelin—Vision blurred—Doxorubicin—liver cancer	0.00106	0.00109	CcSEcCtD
Goserelin—Convulsion—Epirubicin—liver cancer	0.00105	0.00108	CcSEcCtD
Goserelin—Hypertension—Epirubicin—liver cancer	0.00105	0.00108	CcSEcCtD
Goserelin—Ill-defined disorder—Doxorubicin—liver cancer	0.00104	0.00107	CcSEcCtD
Goserelin—Anaemia—Doxorubicin—liver cancer	0.00104	0.00107	CcSEcCtD
Goserelin—Myalgia—Epirubicin—liver cancer	0.00103	0.00106	CcSEcCtD
Goserelin—Chest pain—Epirubicin—liver cancer	0.00103	0.00106	CcSEcCtD
Goserelin—Arthralgia—Epirubicin—liver cancer	0.00103	0.00106	CcSEcCtD
Goserelin—Anxiety—Epirubicin—liver cancer	0.00103	0.00106	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00102	0.00106	CcSEcCtD
Goserelin—Discomfort—Epirubicin—liver cancer	0.00102	0.00105	CcSEcCtD
Goserelin—Malaise—Doxorubicin—liver cancer	0.00101	0.00104	CcSEcCtD
Goserelin—Dry mouth—Epirubicin—liver cancer	0.00101	0.00104	CcSEcCtD
Goserelin—Leukopenia—Doxorubicin—liver cancer	0.001	0.00103	CcSEcCtD
Goserelin—Confusional state—Epirubicin—liver cancer	0.000996	0.00103	CcSEcCtD
Goserelin—Palpitations—Doxorubicin—liver cancer	0.00099	0.00102	CcSEcCtD
Goserelin—Oedema—Epirubicin—liver cancer	0.000988	0.00102	CcSEcCtD
Goserelin—Anaphylactic shock—Epirubicin—liver cancer	0.000988	0.00102	CcSEcCtD
Goserelin—Infection—Epirubicin—liver cancer	0.000981	0.00101	CcSEcCtD
Goserelin—Cough—Doxorubicin—liver cancer	0.000977	0.00101	CcSEcCtD
Goserelin—Shock—Epirubicin—liver cancer	0.000972	0.001	CcSEcCtD
Goserelin—Convulsion—Doxorubicin—liver cancer	0.00097	0.001	CcSEcCtD
Goserelin—Nervous system disorder—Epirubicin—liver cancer	0.000969	0.001	CcSEcCtD
Goserelin—Thrombocytopenia—Epirubicin—liver cancer	0.000967	0.000998	CcSEcCtD
Goserelin—Hypertension—Doxorubicin—liver cancer	0.000967	0.000998	CcSEcCtD
Goserelin—Tachycardia—Epirubicin—liver cancer	0.000964	0.000995	CcSEcCtD
Goserelin—Skin disorder—Epirubicin—liver cancer	0.00096	0.00099	CcSEcCtD
Goserelin—Hyperhidrosis—Epirubicin—liver cancer	0.000955	0.000986	CcSEcCtD
Goserelin—Arthralgia—Doxorubicin—liver cancer	0.000954	0.000984	CcSEcCtD
Goserelin—Chest pain—Doxorubicin—liver cancer	0.000954	0.000984	CcSEcCtD
Goserelin—Myalgia—Doxorubicin—liver cancer	0.000954	0.000984	CcSEcCtD
Goserelin—Anxiety—Doxorubicin—liver cancer	0.00095	0.000981	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000947	0.000977	CcSEcCtD
Goserelin—Discomfort—Doxorubicin—liver cancer	0.000942	0.000972	CcSEcCtD
Goserelin—Anorexia—Epirubicin—liver cancer	0.000942	0.000972	CcSEcCtD
Goserelin—LHCGR—GPCRs, Class A Rhodopsin-like—CCR4—liver cancer	0.000935	0.03	CbGpPWpGaD
Goserelin—Dry mouth—Doxorubicin—liver cancer	0.000933	0.000963	CcSEcCtD
Goserelin—Hypotension—Epirubicin—liver cancer	0.000923	0.000953	CcSEcCtD
Goserelin—Confusional state—Doxorubicin—liver cancer	0.000922	0.000951	CcSEcCtD
Goserelin—Anaphylactic shock—Doxorubicin—liver cancer	0.000914	0.000944	CcSEcCtD
Goserelin—Oedema—Doxorubicin—liver cancer	0.000914	0.000944	CcSEcCtD
Goserelin—Infection—Doxorubicin—liver cancer	0.000908	0.000937	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Epirubicin—liver cancer	0.0009	0.000929	CcSEcCtD
Goserelin—Shock—Doxorubicin—liver cancer	0.000899	0.000928	CcSEcCtD
Goserelin—Nervous system disorder—Doxorubicin—liver cancer	0.000896	0.000925	CcSEcCtD
Goserelin—Thrombocytopenia—Doxorubicin—liver cancer	0.000895	0.000924	CcSEcCtD
Goserelin—Insomnia—Epirubicin—liver cancer	0.000894	0.000922	CcSEcCtD
Goserelin—Tachycardia—Doxorubicin—liver cancer	0.000892	0.000921	CcSEcCtD
Goserelin—Skin disorder—Doxorubicin—liver cancer	0.000888	0.000916	CcSEcCtD
Goserelin—Paraesthesia—Epirubicin—liver cancer	0.000887	0.000916	CcSEcCtD
Goserelin—Hyperhidrosis—Doxorubicin—liver cancer	0.000884	0.000912	CcSEcCtD
Goserelin—Dyspnoea—Epirubicin—liver cancer	0.000881	0.000909	CcSEcCtD
Goserelin—Somnolence—Epirubicin—liver cancer	0.000878	0.000907	CcSEcCtD
Goserelin—Anorexia—Doxorubicin—liver cancer	0.000871	0.000899	CcSEcCtD
Goserelin—Dyspepsia—Epirubicin—liver cancer	0.00087	0.000898	CcSEcCtD
Goserelin—Decreased appetite—Epirubicin—liver cancer	0.000859	0.000886	CcSEcCtD
Goserelin—Hypotension—Doxorubicin—liver cancer	0.000854	0.000882	CcSEcCtD
Goserelin—Fatigue—Epirubicin—liver cancer	0.000852	0.000879	CcSEcCtD
Goserelin—Pain—Epirubicin—liver cancer	0.000845	0.000872	CcSEcCtD
Goserelin—Constipation—Epirubicin—liver cancer	0.000845	0.000872	CcSEcCtD
Goserelin—GNRHR—G alpha (q) signalling events—TRIO—liver cancer	0.000845	0.0271	CbGpPWpGaD
Goserelin—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000833	0.00086	CcSEcCtD
Goserelin—Insomnia—Doxorubicin—liver cancer	0.000827	0.000853	CcSEcCtD
Goserelin—Paraesthesia—Doxorubicin—liver cancer	0.000821	0.000847	CcSEcCtD
Goserelin—Dyspnoea—Doxorubicin—liver cancer	0.000815	0.000841	CcSEcCtD
Goserelin—Feeling abnormal—Epirubicin—liver cancer	0.000814	0.00084	CcSEcCtD
Goserelin—Somnolence—Doxorubicin—liver cancer	0.000813	0.000839	CcSEcCtD
Goserelin—Gastrointestinal pain—Epirubicin—liver cancer	0.000808	0.000834	CcSEcCtD
Goserelin—Dyspepsia—Doxorubicin—liver cancer	0.000805	0.000831	CcSEcCtD
Goserelin—LHCGR—Class A/1 (Rhodopsin-like receptors)—CCR4—liver cancer	0.000801	0.0257	CbGpPWpGaD
Goserelin—Decreased appetite—Doxorubicin—liver cancer	0.000795	0.00082	CcSEcCtD
Goserelin—Fatigue—Doxorubicin—liver cancer	0.000788	0.000813	CcSEcCtD
Goserelin—Urticaria—Epirubicin—liver cancer	0.000785	0.00081	CcSEcCtD
Goserelin—Pain—Doxorubicin—liver cancer	0.000782	0.000807	CcSEcCtD
Goserelin—Constipation—Doxorubicin—liver cancer	0.000782	0.000807	CcSEcCtD
Goserelin—Abdominal pain—Epirubicin—liver cancer	0.000781	0.000806	CcSEcCtD
Goserelin—Body temperature increased—Epirubicin—liver cancer	0.000781	0.000806	CcSEcCtD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—TRIO—liver cancer	0.000756	0.0242	CbGpPWpGaD
Goserelin—Feeling abnormal—Doxorubicin—liver cancer	0.000753	0.000778	CcSEcCtD
Goserelin—Gastrointestinal pain—Doxorubicin—liver cancer	0.000747	0.000772	CcSEcCtD
Goserelin—Hypersensitivity—Epirubicin—liver cancer	0.000728	0.000751	CcSEcCtD
Goserelin—Urticaria—Doxorubicin—liver cancer	0.000726	0.00075	CcSEcCtD
Goserelin—Abdominal pain—Doxorubicin—liver cancer	0.000723	0.000746	CcSEcCtD
Goserelin—Body temperature increased—Doxorubicin—liver cancer	0.000723	0.000746	CcSEcCtD
Goserelin—Asthenia—Epirubicin—liver cancer	0.000709	0.000732	CcSEcCtD
Goserelin—Pruritus—Epirubicin—liver cancer	0.000699	0.000721	CcSEcCtD
Goserelin—Diarrhoea—Epirubicin—liver cancer	0.000676	0.000698	CcSEcCtD
Goserelin—Hypersensitivity—Doxorubicin—liver cancer	0.000673	0.000695	CcSEcCtD
Goserelin—Asthenia—Doxorubicin—liver cancer	0.000656	0.000677	CcSEcCtD
Goserelin—Dizziness—Epirubicin—liver cancer	0.000653	0.000674	CcSEcCtD
Goserelin—Pruritus—Doxorubicin—liver cancer	0.000647	0.000668	CcSEcCtD
Goserelin—Vomiting—Epirubicin—liver cancer	0.000628	0.000648	CcSEcCtD
Goserelin—Diarrhoea—Doxorubicin—liver cancer	0.000625	0.000646	CcSEcCtD
Goserelin—Rash—Epirubicin—liver cancer	0.000623	0.000643	CcSEcCtD
Goserelin—Dermatitis—Epirubicin—liver cancer	0.000622	0.000642	CcSEcCtD
Goserelin—Headache—Epirubicin—liver cancer	0.000619	0.000639	CcSEcCtD
Goserelin—LHCGR—GPCR ligand binding—CCR4—liver cancer	0.00061	0.0196	CbGpPWpGaD
Goserelin—Dizziness—Doxorubicin—liver cancer	0.000604	0.000624	CcSEcCtD
Goserelin—Nausea—Epirubicin—liver cancer	0.000587	0.000606	CcSEcCtD
Goserelin—Vomiting—Doxorubicin—liver cancer	0.000581	0.0006	CcSEcCtD
Goserelin—Rash—Doxorubicin—liver cancer	0.000576	0.000595	CcSEcCtD
Goserelin—Dermatitis—Doxorubicin—liver cancer	0.000576	0.000594	CcSEcCtD
Goserelin—Headache—Doxorubicin—liver cancer	0.000573	0.000591	CcSEcCtD
Goserelin—Nausea—Doxorubicin—liver cancer	0.000543	0.00056	CcSEcCtD
Goserelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCR4—liver cancer	0.000536	0.0172	CbGpPWpGaD
Goserelin—GNRHR—G alpha (q) signalling events—PRKCE—liver cancer	0.000466	0.015	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CHN2—liver cancer	0.000465	0.0149	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—IFT88—liver cancer	0.000425	0.0136	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCE—liver cancer	0.000417	0.0134	CbGpPWpGaD
Goserelin—GNRHR—GPCR ligand binding—CCR4—liver cancer	0.000408	0.0131	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—TRIO—liver cancer	0.00036	0.0115	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—CCR4—liver cancer	0.000345	0.0111	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—TRIO—liver cancer	0.000327	0.0105	CbGpPWpGaD
Goserelin—GNRHR—G alpha (q) signalling events—F2—liver cancer	0.000324	0.0104	CbGpPWpGaD
Goserelin—LHCGR—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.00032	0.0103	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—CCR4—liver cancer	0.000313	0.01	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CHN2—liver cancer	0.000311	0.00998	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—F2—liver cancer	0.00029	0.00929	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IFT88—liver cancer	0.000284	0.00913	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—SHC3—liver cancer	0.00026	0.00836	CbGpPWpGaD
Goserelin—LHCGR—GPCR ligand binding—F2—liver cancer	0.000244	0.00783	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—TRIO—liver cancer	0.000241	0.00773	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—CCR4—liver cancer	0.000231	0.00741	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—TRIO—liver cancer	0.000219	0.00702	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—liver cancer	0.000217	0.00698	CbGpPWpGaD
Goserelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.000214	0.00688	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—CCR4—liver cancer	0.00021	0.00673	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—FST—liver cancer	0.000202	0.00649	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PRKCE—liver cancer	0.000199	0.00637	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TRIO—liver cancer	0.000193	0.00619	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CCR4—liver cancer	0.000185	0.00594	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PRKCE—liver cancer	0.00018	0.00579	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—CSF2—liver cancer	0.000176	0.00564	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—SHC3—liver cancer	0.000174	0.0056	CbGpPWpGaD
Goserelin—GNRHR—GPCR ligand binding—F2—liver cancer	0.000163	0.00524	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—CSF2—liver cancer	0.000159	0.00512	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ADAM17—liver cancer	0.000146	0.00469	CbGpPWpGaD
Goserelin—GNRHR—G alpha (q) signalling events—PIK3CA—liver cancer	0.000145	0.00464	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—liver cancer	0.000141	0.00452	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—F2—liver cancer	0.000138	0.00442	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PSMA4—liver cancer	0.000137	0.00441	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PSMD10—liver cancer	0.000137	0.00441	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FST—liver cancer	0.000135	0.00434	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PRKCE—liver cancer	0.000133	0.00426	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CG—liver cancer	0.000132	0.00423	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	0.000129	0.00415	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TRIO—liver cancer	0.000129	0.00414	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—F2—liver cancer	0.000125	0.00402	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CCR4—liver cancer	0.000124	0.00397	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PRKCE—liver cancer	0.000121	0.00387	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CG—liver cancer	0.00012	0.00384	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	0.00012	0.00384	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—CSF2—liver cancer	0.000118	0.00377	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CD—liver cancer	0.000116	0.00372	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	0.000115	0.00368	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—CSF2—liver cancer	0.000107	0.00343	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PRKCE—liver cancer	0.000107	0.00342	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CD—liver cancer	0.000105	0.00338	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CB—liver cancer	0.000101	0.00324	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—IGF2—liver cancer	0.000101	0.00324	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ADAM17—liver cancer	9.79e-05	0.00314	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CSF2—liver cancer	9.42e-05	0.00302	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—RAF1—liver cancer	9.4e-05	0.00302	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—H2AFX—liver cancer	9.29e-05	0.00298	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—IL2—liver cancer	9.28e-05	0.00298	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—F2—liver cancer	9.23e-05	0.00296	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PSMA4—liver cancer	9.2e-05	0.00295	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PSMD10—liver cancer	9.2e-05	0.00295	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CB—liver cancer	9.18e-05	0.00295	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CG—liver cancer	8.83e-05	0.00283	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—IL2—liver cancer	8.43e-05	0.0027	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TERT—liver cancer	8.4e-05	0.00269	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—F2—liver cancer	8.38e-05	0.00269	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3CG—liver cancer	8.02e-05	0.00257	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CD—liver cancer	7.76e-05	0.00249	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—KDR—liver cancer	7.68e-05	0.00246	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MAPK14—liver cancer	7.63e-05	0.00245	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ESR1—liver cancer	7.49e-05	0.0024	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—F2—liver cancer	7.39e-05	0.00237	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PRKCE—liver cancer	7.13e-05	0.00229	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3CG—liver cancer	7.08e-05	0.00227	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—APC—liver cancer	7.08e-05	0.00227	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3CD—liver cancer	7.05e-05	0.00226	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CB—liver cancer	6.77e-05	0.00217	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IGF2—liver cancer	6.75e-05	0.00217	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—BRAF—liver cancer	6.65e-05	0.00213	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CSF2—liver cancer	6.31e-05	0.00202	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—RAF1—liver cancer	6.29e-05	0.00202	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3CD—liver cancer	6.22e-05	0.002	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—H2AFX—liver cancer	6.22e-05	0.00199	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—IL2—liver cancer	6.21e-05	0.00199	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CA—liver cancer	6.16e-05	0.00198	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—SERPINE1—liver cancer	6.15e-05	0.00197	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3CB—liver cancer	6.14e-05	0.00197	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—KRAS—liver cancer	6.09e-05	0.00195	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—IL2—liver cancer	5.64e-05	0.00181	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TERT—liver cancer	5.62e-05	0.0018	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CA—liver cancer	5.59e-05	0.0018	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—RAF1—liver cancer	5.55e-05	0.00178	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MTOR—liver cancer	5.42e-05	0.00174	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3CB—liver cancer	5.42e-05	0.00174	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—HRAS—liver cancer	5.18e-05	0.00166	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—KDR—liver cancer	5.14e-05	0.00165	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MAPK14—liver cancer	5.11e-05	0.00164	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CDKN1B—liver cancer	5.09e-05	0.00163	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—AKT1—liver cancer	5.03e-05	0.00162	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ESR1—liver cancer	5.01e-05	0.00161	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CASP3—liver cancer	4.99e-05	0.0016	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—IL2—liver cancer	4.98e-05	0.0016	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—IL6—liver cancer	4.95e-05	0.00159	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—F2—liver cancer	4.95e-05	0.00159	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CCND1—liver cancer	4.85e-05	0.00156	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—JUN—liver cancer	4.84e-05	0.00155	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CTNNB1—liver cancer	4.81e-05	0.00154	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—APC—liver cancer	4.74e-05	0.00152	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CG—liver cancer	4.74e-05	0.00152	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MMP9—liver cancer	4.71e-05	0.00151	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CDKN1A—liver cancer	4.7e-05	0.00151	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MAPK8—liver cancer	4.58e-05	0.00147	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—AKT1—liver cancer	4.57e-05	0.00147	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—BRAF—liver cancer	4.45e-05	0.00143	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—VEGFA—liver cancer	4.23e-05	0.00136	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—STAT3—liver cancer	4.19e-05	0.00134	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CD—liver cancer	4.16e-05	0.00134	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CA—liver cancer	4.12e-05	0.00132	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—SERPINE1—liver cancer	4.12e-05	0.00132	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—KRAS—liver cancer	4.08e-05	0.00131	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—MYC—liver cancer	3.89e-05	0.00125	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TGFB1—liver cancer	3.88e-05	0.00125	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3CA—liver cancer	3.75e-05	0.0012	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—RAF1—liver cancer	3.72e-05	0.00119	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MTOR—liver cancer	3.63e-05	0.00116	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CB—liver cancer	3.63e-05	0.00116	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—KRAS—liver cancer	3.6e-05	0.00115	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—HRAS—liver cancer	3.47e-05	0.00111	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CDKN1B—liver cancer	3.41e-05	0.00109	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—AKT1—liver cancer	3.37e-05	0.00108	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CASP3—liver cancer	3.34e-05	0.00107	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IL2—liver cancer	3.33e-05	0.00107	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—IL6—liver cancer	3.32e-05	0.00106	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3CA—liver cancer	3.31e-05	0.00106	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CCND1—liver cancer	3.25e-05	0.00104	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—JUN—liver cancer	3.24e-05	0.00104	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CTNNB1—liver cancer	3.22e-05	0.00103	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TP53—liver cancer	3.2e-05	0.00103	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MMP9—liver cancer	3.15e-05	0.00101	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CDKN1A—liver cancer	3.14e-05	0.00101	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MAPK8—liver cancer	3.07e-05	0.000984	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—AKT1—liver cancer	3.06e-05	0.000982	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HRAS—liver cancer	3.06e-05	0.000981	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—IL6—liver cancer	2.93e-05	0.000939	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—VEGFA—liver cancer	2.83e-05	0.000909	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—STAT3—liver cancer	2.8e-05	0.0009	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—AKT1—liver cancer	2.7e-05	0.000866	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—MYC—liver cancer	2.61e-05	0.000836	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TGFB1—liver cancer	2.6e-05	0.000834	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—KRAS—liver cancer	2.41e-05	0.000773	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CA—liver cancer	2.21e-05	0.00071	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TP53—liver cancer	2.14e-05	0.000687	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—HRAS—liver cancer	2.05e-05	0.000657	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IL6—liver cancer	1.96e-05	0.000629	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AKT1—liver cancer	1.81e-05	0.00058	CbGpPWpGaD
